BIPOLAR DISORDER TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Bipolar Disorder Treatment Market – Driver

Increasing product approvals are expected to propel the market growth over the forecast period

To treat adults with schizophrenia and as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults, the key market players are focusing on getting product approvals from regulatory authorities is expected to drive the bipolar disorder treatment market over the forecast period. For instance, in January 2023, Luye Pharma Group, an international pharmaceutical company, announced it had received FDA approval for its Rykindo (risperidone), which is an extended-release injectable suspension administered via intramuscular injection once every two weeks.

Global Bipolar Disorder Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a minor negative impact on the global bipolar disorder treatment market. For instance, in September 2021, an article published ‘Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review’, focused on how the clinical course of bipolar disorder (BD) is affected by social isolation, stifling rules, lifestyle changes, and biological circadian rhythm abnormalities brought on by the COVID-19 pandemic, or infection-related worries. According to several research, persons with bipolar disorder (BD) experienced fewer relapses or symptoms that worsened during the pandemic, or less severe psychiatric symptoms and greater feelings of well-being than they had before the pandemic. Patients with bipolar disorder (BD) showed less psychological discomfort than those with major depressive disorder (MDD).

Global Bipolar Disorder Treatment Market: Restraint

Side effects associated with drugs

Side effects associated with drugs used in the treatment of bipolar disorder are expected to be a factor negatively affecting the growth of the market up to a certain extent, as patients hesitate to undergo medication therapy due to fear of the same. For instance, some of the medications including carbamazepine, Divalproex sodium, and Lithium used in the treatment of bipolar disorder have some side effects such as nausea, tremors, sexual problem, impaired memory, muscle weakness, decreased thyroid function, liver and kidney damage, skin reactions, and others.